MARKET

KALV

KALV

Kalvista Pharm
NASDAQ
18.36
-0.97
-5.02%
Pre Market: 18.31 -0.05 -0.27% 07:01 03/31 EDT
OPEN
18.96
PREV CLOSE
19.33
HIGH
19.50
LOW
18.24
VOLUME
479
TURNOVER
0
52 WEEK HIGH
19.95
52 WEEK LOW
9.24
MARKET CAP
928.03M
P/E (TTM)
-8.0877
1D
5D
1M
3M
1Y
5Y
1D
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From EKTERLY Study
NASDAQ · 1d ago
KalVista Pharma Presents New Interim Results From KONFIDENT-KID Clinical Trial Evaluating EKTERLY For On-Demand Treatment Of HAE Attacks In Children Ages 2-11 At 2026 Global Angioedema Leadership Conference
Benzinga · 1d ago
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
TipRanks · 1d ago
KalVista reports positive interim Phase 3 data for oral pediatric HAE drug sebetralstat
Reuters · 1d ago
KALVISTA PHARMACEUTICALS INC - TO FILE US NDA FOR SEBETRALSTAT IN Q3 2026; LAUNCH ANTICIPATED IN 2027
Reuters · 1d ago
Weekly Report: what happened at KALV last week (0323-0327)?
Weekly Report · 1d ago
KalVista Pharmaceuticals (KALV) Gets a Buy from Stifel Nicolaus
TipRanks · 1d ago
Major KalVista Stakeholder Makes Eye-Catching Move With Fresh Stock Sale
TipRanks · 3d ago
More
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

Webull offers Kalvista Pharmaceuticals Inc stock information, including NASDAQ: KALV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALV stock methods without spending real money on the virtual paper trading platform.